Jon Stonehouse, BioCryst CEO
October 14, 2025 11:13 AM EDTUpdated October 17, 08:45 AM
Deals

BioCryst to ac­quire As­tria for $700M, adding a sec­ond HAE drug

Elizabeth Cairns

Senior biopharma journalist

BioCryst Phar­ma­ceu­ti­cals plans to buy As­tria Ther­a­peu­tics for around $700 mil­lion in cash and stock.

The deal, an­nounced Tues­day, means BioCryst …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sum­mit plans to take lung can­cer drug to FDA, plots com­bo use and study changes

FDA staffing da­ta show his­toric num­bers of de­par­tures in fis­cal 2025

An­throp­ic de­buts first AI prod­uct for life sci­ences as it builds out bio team

Three block­busters prompt CBO to raise or­phan drug ex­pan­sion cost es­ti­mate to $8.8B over 10 years

RAPT, Jey­ou are itch­ing to start Phase 3 af­ter en­cour­ag­ing mid-stage re­sults in ur­ticaria

sponsored

The ad­vent of dig­i­tal ther­a­peu­tics and what it means for health­care

A service from the Financial Times